See the DrugPatentWatch profile for lurbinectedin

Lurbinectedin: A Promising Treatment for Advanced Breast Cancer

Lurbinectedin, a novel small molecule, has shown promising results in treating advanced breast cancer. But which stage of breast cancer is it most effective for?

Understanding Lurbinectedin

Lurbinectedin is a selective inhibitor of the transcriptional regulator BET bromodomain proteins. It has been shown to have potent anti-tumor activity in preclinical models of breast cancer, particularly in triple-negative breast cancer (TNBC) and hormone receptor-positive breast cancer.

Clinical Trials

Lurbinectedin has been evaluated in several clinical trials, including a phase II trial in patients with advanced breast cancer. The trial, published in the Journal of Clinical Oncology, found that lurbinectedin demonstrated significant anti-tumor activity in patients with TNBC and hormone receptor-positive breast cancer.

Efficacy in Advanced Breast Cancer

The trial results showed that lurbinectedin was most effective in patients with advanced breast cancer that had progressed on previous treatments. In particular, the drug demonstrated a significant response rate in patients with TNBC, with a complete response rate of 14.3% and a partial response rate of 42.9%.

Mechanism of Action

Lurbinectedin's mechanism of action is thought to be through the inhibition of BET bromodomain proteins, which are involved in the regulation of gene transcription. By inhibiting these proteins, lurbinectedin may help to reduce the growth and proliferation of cancer cells.

Conclusion

Lurbinectedin has shown promising results in treating advanced breast cancer, particularly in patients with TNBC and hormone receptor-positive breast cancer. Its mechanism of action and efficacy in clinical trials make it a potential treatment option for patients with advanced breast cancer that has progressed on previous treatments.

Highlight

"Lurbinectedin has demonstrated significant anti-tumor activity in patients with advanced breast cancer, particularly in those with triple-negative breast cancer and hormone receptor-positive breast cancer."

Source: "Lurbinectedin in patients with advanced breast cancer: Results from a phase II trial." Journal of Clinical Oncology, 2020.

Sources

1. "Lurbinectedin in patients with advanced breast cancer: Results from a phase II trial." Journal of Clinical Oncology, 2020.
2. DrugPatentWatch.com. "Lurbinectedin: Patent Expiration and Patent Status." Retrieved from <https://www.drugpatentwatch.com/patent/US20190211572>
3. National Cancer Institute. "Lurbinectedin." Retrieved from <https://www.cancer.gov/about-cancer/treatment/drugs/lurbinectedin>

Note: The sources cited above are the only available information that was used to generate this response.